Synthorx Inc (NASDAQ:THOR) has been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus target price of $26.67 for the company and are predicting that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also given Synthorx an industry rank of 50 out of 255 based on the ratings given to its competitors.
A number of analysts have weighed in on the stock. Svb Leerink restated an “outperform” rating on shares of Synthorx in a research note on Monday, March 18th. Zacks Investment Research lowered shares of Synthorx from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. Leerink Swann assumed coverage on shares of Synthorx in a research note on Friday, March 15th. They set an “outperform” rating for the company. HC Wainwright assumed coverage on shares of Synthorx in a research note on Wednesday, January 2nd. They set a “buy” rating and a $30.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on shares of Synthorx in a research note on Wednesday, January 2nd. They set a “buy” rating and a $21.00 price objective for the company.
NASDAQ:THOR traded down $0.42 on Tuesday, reaching $16.92. 43,255 shares of the stock traded hands, compared to its average volume of 72,975. The firm has a market cap of $543.84 million and a P/E ratio of -2.57. Synthorx has a 12 month low of $11.00 and a 12 month high of $23.53.
Synthorx (NASDAQ:THOR) last released its quarterly earnings data on Tuesday, March 12th. The medical instruments supplier reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.77). Sell-side analysts anticipate that Synthorx will post -1.46 EPS for the current fiscal year.
Synthorx Company Profile
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Featured Article: What are Bollinger Bands?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.